Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546082 | 1.00 | MAOA (0.57) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| SCHEMBL13089938 | 1.00 | MAOA (0.57) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| Hydrochloric Acid SCHEMBL1382270 | 0.99 | MAOA (0.56) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| Trifluoroacetic Acid SCHEMBL1380365 | 0.96 | MAOA (0.53) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| SCHEMBL13089937 | 0.94 | MAOA (0.58) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| SCHEMBL12605125 | 0.94 | MAOA (0.58) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| Hydrochloric Acid SCHEMBL1382355 | 0.94 | MAOA (0.57) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| Trifluoroacetic Acid SCHEMBL1384535 | 0.90 | MAOA (0.54) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| SCHEMBL1985755 | 0.89 | MAOA (0.59) | MAOAMAOBCYP3A4CYP2C19CALML3 | |
| SCHEMBL23311430 | 0.89 | MAOA (0.74) | MAOAMAOBCYP3A4CYP2C19CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | claimed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8461188-B2 | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use | TRIUS THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461188-B2 | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use | TRIUS THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CYP3A4 46/4885 |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | MAOA 4539/4885MAOB 4420/4885CYP3A4 4049/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CYP3A4 46/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | MAOA 3819/4885MAOB 3591/4885CYP3A4 93/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CYP3A4 46/4885 |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | MAOA 2505/4885MAOB 1905/4885CYP3A4 46/4885 |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | MAOA 4539/4885MAOB 4420/4885CYP3A4 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.